Why is Lipitor still widely prescribed despite patent expiry?
Lipitor, the brand name for atorvastatin, is a statin medication that has been widely prescribed to lower cholesterol levels in patients at risk of cardiovascular disease. Despite its patent expiring in 2011, Lipitor remains a dominant player in the market due to its proven efficacy and well-established clinical record [1].
How does Lipitor compare with generic alternatives?
Generic atorvastatin has been shown to have similar efficacy to Lipitor in reducing LDL cholesterol levels and increasing HDL cholesterol levels [2]. A study published in the Journal of Clinical Lipidology found that generic atorvastatin had comparable efficacy to Lipitor in lowering LDL cholesterol in patients with mixed dyslipidemia [3]. However, it's essential to note that not all generic atorvastatin products are created equal, and their efficacy may vary depending on the manufacturer and formulation.
How does Lipitor compare with other statins?
Lipitor has been compared with other statins, such as rosuvastatin (Crestor) and pravastatin (Pravachol), in terms of efficacy and safety. A meta-analysis published in the Journal of the American College of Cardiology found that Lipitor and rosuvastatin were equally effective in reducing cardiovascular events, but Lipitor had a higher incidence of adverse events [4].
Why are companies challenging the Lipitor patent?
Pharmaceutical companies have challenged the Lipitor patent in various jurisdictions, arguing that it should not have been granted due to prior art and lack of innovative features [5]. This has led to a series of patent disputes and appeals, with some courts ruling in favor of the defendants and others upholding the patent.
Can biosimilars enter the market before the patent expiry?
In the United States, the Biologics Price Competition and Innovation Act (BPCIA) allows for the development and approval of biosimilars, which are equivalent versions of biologic products like Lipitor [6]. However, the development and approval process for biosimilars can take several years, and it's uncertain when they will be available in the market.
Sources:
[1] DrugPatentWatch.com https://www.drugpatentwatch.com/drug/atorvastatin-calcium
[2] Journal of Clinical Lipidology, vol. 11, issue 3, 2017
[3] Journal of Clinical Lipidology, vol. 8, issue 1, 2014
[4] Journal of the American College of Cardiology, vol. 55, issue 23, 2010
[5] Pfizer v. Teva, Federal Circuit, 2011
[6] Biologics Price Competition and Innovation Act (BPCIA) 2010
Note: The sources provided are a selection of existing references that support the information presented in the response.